The European Medicines Agency (EMA) and the European Commission are providing guidance to help pharmaceutical companies responsible for both human and veterinary medicines prepare for the United Kingdom’s (UK) withdrawal from the European Union (EU), a process known as ‘Brexit’.
This aims to ensure that companies are ready to take the necessary steps to enable undisrupted supply of their medicines in the EU for the benefit of patients, based on the assumption that the UK will become a third country as of 30 March 2019.
On this page
- Guidance on centrally authorised products
- Industry survey (for centrally authorised products)
- Guidance on nationally authorised products
- Stakeholder meetings
Guidance on centrally authorised products
Companies should check this page regularly for guidance on the consequences of Brexit, as EMA and the European Commission are preparing a series of guidance documents.